Lancet Review Confirms Billions of mRNA Doses Cut COVID Deaths 94% as Access Gaps Persist
Updated
Updated · Euronews · Jul 1
Lancet Review Confirms Billions of mRNA Doses Cut COVID Deaths 94% as Access Gaps Persist
3 articles · Updated · Euronews · Jul 1
Summary
A Lancet review of billions of administered mRNA vaccine doses found compelling evidence the shots remain safe and highly effective against infectious diseases, especially severe COVID-19 outcomes.
The analysis estimated 87% effectiveness against documented SARS-CoV-2 infection, 93% against hospitalization and 94% against death within 14 to 42 days after vaccination; booster doses restored protection that waned over time.
Serious adverse events — including myocarditis, pericarditis and anaphylaxis — were reported as very rare, while most reactions such as sore arms, fatigue and fever were mild to moderate and resolved within days.
Researchers said the platform has proved effective across age groups, pregnancy and immunocompromised populations, and could also support personalized cancer vaccines tailored to patients and tumor profiles.
Improved storage options may help reach remote areas faster, but the authors said wider manufacturing, technology transfer and stronger regulation in low- and middle-income countries are still needed to make mRNA vaccines a global public good.
Myocarditis rates from mRNA vaccines have dropped to normal levels. What scientific or manufacturing changes made this possible?
With global production expanding, what ensures new regional vaccine hubs can survive financially without guaranteed international purchase agreements?
How are personalized mRNA vaccines teaching immune systems to fight previously untreatable cancers like pancreatic cancer?
mRNA Vaccines After COVID-19: Confirmed Safety, Global Access Challenges, and the Next Frontier in Medicine
Overview
A comprehensive review published in The Lancet in June 2026 synthesizes extensive data collected between 2020 and 2025, providing strong evidence that mRNA vaccines against COVID-19 are both safe and effective. The findings show consistent benefits and minimal risks, based on billions of doses given worldwide. This vast real-world dataset highlights the robust performance of mRNA vaccines and their vital role in global public health. Transparent reporting of rare adverse events has been key to post-market surveillance, helping to build public trust and support ongoing monitoring for long-term safety.